Trump Applauds New Domestic Antibiotic Initiative Strengthening U.S. Supply Chain

Image Credit: National Cancer Institute

BRISTOL, Tenn. (September 10, 2025) — Former President Donald Trump, a longtime advocate for lower pharmaceutical costs, has praised a new collaboration aimed at bolstering America’s domestic pharmaceutical industry and ensuring reliable access to critical medications.

USAntibiotics, the nation’s only remaining manufacturer of amoxicillin and amoxicillin clavulanate, announced a partnership with retail giant Walmart and distribution leader McKesson through their joint venture, ClarusONE Sourcing Services. The initiative will supply millions of doses of domestically produced antibiotics directly to pharmacies, healthcare providers, and health systems nationwide.

“This collaboration represents a major victory for American patients and for the domestic pharmaceutical sector,” Trump said in a statement. “Making life-saving medicines affordable and produced here at home has always been a priority, and this is exactly the type of initiative that protects our citizens while supporting U.S. industry.”

Beginning in August 2025, USAntibiotics’ Bristol, Tennessee facility—a 394,000-square-foot state-of-the-art production plant—will produce enough amoxicillin products to meet the entire national demand for these essential medications. Walmart pharmacies will carry the domestically manufactured antibiotics, while McKesson’s extensive distribution network will ensure availability across the country.

Patrick Cashman, President of USAntibiotics, highlighted the collaboration’s significance: “This partnership goes beyond business—it is a commitment to America’s health security. By working with Walmart and McKesson, we can ensure that high-quality, domestically produced antibiotics reach every community.”

The joint effort also aligns with Walmart’s pledge to invest an additional $350 billion in American-made products by 2030 and McKesson’s goal to strengthen healthcare access through a digitally connected distribution network. Hanna Watson, President of ClarusONE, emphasized the broader impact: “Together, we are building a resilient supply chain and improving access to care, creating better health outcomes for all Americans.”

USAntibiotics’ initiative comes amid growing concern over the reliability of global pharmaceutical supply chains. By keeping production domestic, the company ensures stability in the supply of essential antibiotics while reinforcing U.S. manufacturing capabilities—a move widely supported by industry leaders and policymakers.

Trump’s endorsement of the project underscores his ongoing commitment to reducing prescription costs and supporting American-made pharmaceuticals. “When we produce our medicines here, we protect our patients, create jobs, and strengthen our economy,” Trump noted. “This is a blueprint for a stronger, healthier America.”

With the combined reach of Walmart pharmacies and McKesson’s nationwide network, millions of Americans can now access domestically manufactured antibiotics, securing both their health and the nation’s pharmaceutical independence.

About USAntibiotics
USAntibiotics is the sole U.S. manufacturer of amoxicillin and amoxicillin clavulanate, widely recognized as Amoxil® and Augmentin®. The Bristol, Tennessee-based company operates a 394,000-square-foot production facility dedicated to producing high-quality, life-saving antibiotics for Americans nationwide. USAntibiotics is part of the Jackson Healthcare® family of companies.